KEGG analysis identified significant associations with regorafenib-related liver failure for multiple pathways, including the MAPK signaling pathway, Rap1 signaling pathway, PI3K-Akt signaling pathway, and Pathways in cancer. This evidence concerns the gene AKT1 and liver failure.